50894-01-4

Basic information

• Product Name: 5-pyridin-2-ylmethyl 3-isopropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• Synonyms: 5-pyridin-2-ylmethyl 3-isopropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• CAS NO: 50894-01-4
• Molecular Weight: 451.479
• Mol File: 50894-01-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-pyridin-2-ylmethyl 3-isopropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 5-pyridin-2-ylmethyl 3-isopropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate(50894-01-4)
• EPA Substance Registry System: 5-pyridin-2-ylmethyl 3-isopropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate(50894-01-4)

Safety Data

• Hazardous Substances Data: 50894-01-4(Hazardous Substances Data)

Upstream product

• 542-08-5 isopropyl acetoacetate 
• 586-98-1 2-Hydroxymethylpyridine 
• 50899-06-4 pyridine-2-ylmethyl-3-oxobutanoate 
• 14205-46-0 isopropyl 3-aminocrotonate 
• 552-89-6 2-nitro-benzaldehyde 
• 40100-28-5 isopropyl 3-aminocrotonate 

Relevant articles and documents

Unsymmetric dihydropyridines bearing 2-pyridyl methyl carboxylate as modulators of P-glycoprotein; Synthesis and biological evaluation in resistant and non-resistant cancer cells

Multi-drug resistance (MDR) in cancer cells is often associated with overexpression of P-glycoprotein (P-gp or ABCB1 or MDR1); therefore, modulators of this transporter might be helpful in overcoming MDR. In this study, 16 novel unsymmetrical dihydropyridine (DHP) derivatives bearing 2-pyridyl methyl carboxylate at C3 and a nitroimidazole or nitrophenyl ring at C4 positions of the DHP ring were synthesized. Their cytotoxicity was tested against four human cancer cells by MTT assay. The reversal capacity of MDR was examined in P-gp overexpressing cells (MES-SA/DX5) by measuring the alteration of doxorubicin's IC50 and performing flow cytometric determination of intracellular rhodamine 123 accumulation. The calcium channel blocking (CCB) activity, as a side effect of DHPs, was tested on the ileum of a guinea pig. Molecular docking was performed to explain the binding mode of compounds. Two derivatives, 4a and 4c, containing 4-nitrophenyl at C4 and possessing methyl (4a) and iso-propyl (4c) carboxylates at the C5 position of DHP core demonstrated superior cytotoxic and MDR reversal activities and lower CCB effect. Docking analysis confirmed the importance of the 4-nitrophenyl ring for P-gp inhibitory activity. Some of the synthesized DHP derivatives with considerable MDR reversal capacity could be promising compounds for further discovery of useful agents for management of drug resistant cancer.